Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evolocumab plus intensive statin therapy in acute ischemic stroke
ChiCTR2300077694Phase 4Not yet recruiting
- Sponsor
- Shenzhen Longgang District Maternity & Child Healthcare Hospital
- Start
- Jul 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in ischemic stroke comparing Treatment group: evolocumab + intensive statin with Control group: placebo + intensive statin (2 arms). Primary endpoints: Modified Rankin Scale score at 90 days and NIH Stroke Scale score at 90 days. Planned start Jul 2023; status: not yet recruiting.
02
Drugs
evolocumab
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on ChiCTR2300077694.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300077694.